- Home
- ACAD vs MMSI Comparison
ACAD vs MMSI Comparison
Compare ACAD & MMSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- MMSI
- Stock Information
- Founded
- ACAD 1993
- MMSI 1987
- Country
- ACAD United States
- MMSI United States
- Employees
- ACAD N/A
- MMSI N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- MMSI Medical/Dental Instruments
- Sector
- ACAD Health Care
- MMSI Health Care
- Exchange
- ACAD Nasdaq
- MMSI Nasdaq
- Market Cap
- ACAD 4.3B
- MMSI 5.0B
- IPO Year
- ACAD 2004
- MMSI 1990
- Fundamental
- Price
- ACAD $21.31
- MMSI $83.74
- Analyst Decision
- ACAD Buy
- MMSI Strong Buy
- Analyst Count
- ACAD 21
- MMSI 8
- Target Price
- ACAD $29.25
- MMSI $107.50
- AVG Volume (30 Days)
- ACAD 2.3M
- MMSI 752.4K
- Earning Date
- ACAD 11-05-2025
- MMSI 10-30-2025
- Dividend Yield
- ACAD N/A
- MMSI N/A
- EPS Growth
- ACAD 615.00
- MMSI N/A
- EPS
- ACAD 1.33
- MMSI 1.97
- Revenue
- ACAD $1,018,885,000.00
- MMSI $1,432,816,000.00
- Revenue This Year
- ACAD $14.01
- MMSI $12.79
- Revenue Next Year
- ACAD $11.81
- MMSI $6.34
- P/E Ratio
- ACAD $16.07
- MMSI $42.32
- Revenue Growth
- ACAD 14.41
- MMSI 10.11
- 52 Week Low
- ACAD $13.40
- MMSI $79.10
- 52 Week High
- ACAD $26.65
- MMSI $111.45
- Technical
- Relative Strength Index (RSI)
- ACAD 33.94
- MMSI 41.24
- Support Level
- ACAD $21.32
- MMSI $80.05
- Resistance Level
- ACAD $21.96
- MMSI $84.84
- Average True Range (ATR)
- ACAD 0.60
- MMSI 1.87
- MACD
- ACAD -0.10
- MMSI 0.12
- Stochastic Oscillator
- ACAD 30.11
- MMSI 45.90
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About MMSI Merit Medical Systems Inc.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.